Checkpoint Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Accounts Payable and Accrued Expenses

3 Months Ended

Mar. 31, 2021

Note 7 - Accounts Payable and Accrued Expenses

At March 31, 2021 and December 31, 2020, accounts payable and accrued expenses consisted of the following ($ in thousands):


	March 31,		December 31,
	2021		2020
Accounts payable	$	3,528	$	3,438
Accrued compensation		155		535
Research and development		2,019		2,009
Other		374		385
Total accounts payable and accrued expenses	$	6,076	$	6,367